Basel Medical Group Ltd (BMGL) Stock AnalysisBMGLBasel Medical Group Ltd

Basel Medical Group Ltd is a holding company, which operates through its subsidiary, Basel Medical Group Pte. Ltd. It provides a wide spectrum of general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Its orthopedic treatments and surgery include non-surgical treatments, such as medications, injections, splinting and physiotherapy, and surgical orthopedic procedures, including minimally invasive treatments for complex surgeries. Its rehabilitative therapy provides in-house physiotherapy treatments, including post-surgery rehabilitation, as well as sports therapy. Its neurosurgical care covers treatments involving spinal and brain conditions, from headaches and brain tumors to spinal issues, aneurysms and strokes. It also specializes in diagnostic imaging and outpatient care. It operates in the Healthcare sector.

Basel Medical Group Ltd (BMGL) is currently not a strong buy due to its recent performance and financial instability. The stock has seen a significant decline of 78.17% over the past year and has a current price of $5.24, which is below its 200-day simple moving average of $7.905. Although it regained Nasdaq compliance on July 10, 2026, this was after a reverse stock split, which often raises concerns among investors. The RSI is at 50.645, indicating a neutral momentum, and the forward P/E ratio is at 0, suggesting uncertainty about future earnings. The main risk is the high debt to equity ratio of 137.69%, which indicates potential financial distress.